688235 百济神州
午间休市 11-07 11:29:27
资讯
新帖
简况
百济神州(06160)Q3单季度营收突破百亿规模 上调全年业绩指引
智通财经网 · 11-06 20:45
百济神州(06160)Q3单季度营收突破百亿规模 上调全年业绩指引
百济神州：百悦泽®在美国市场地位领先以及其在全球其他重要市场持续扩张调整2025年营业收入预测为362亿元至381亿元
证券之星 · 11-06 19:50
百济神州：百悦泽®在美国市场地位领先以及其在全球其他重要市场持续扩张调整2025年营业收入预测为362亿元至381亿元
百济神州：第三季度总收入达14亿美元，同比增长41%
金融界 · 11-06 19:10
百济神州：第三季度总收入达14亿美元，同比增长41%
博时基金万琼旗下博时恒生医疗保健ETF三季报最新持仓，重仓百济神州
证券之星 · 10-28
博时基金万琼旗下博时恒生医疗保健ETF三季报最新持仓，重仓百济神州
银华基金马君旗下银华国证港股通创新药ETF三季报最新持仓，重仓百济神州
证券之星 · 10-27
银华基金马君旗下银华国证港股通创新药ETF三季报最新持仓，重仓百济神州
每周股票复盘：百济神州（688235）英文名变更为BeOne Medicines
证券之星 · 10-26
每周股票复盘：百济神州（688235）英文名变更为BeOne Medicines
百济神州（688235）披露将举行业绩电话会议，10月22日股价下跌0.22%
证券之星 · 10-22
百济神州（688235）披露将举行业绩电话会议，10月22日股价下跌0.22%
三款国产抗癌药卖出天价BD！信达生物114亿美元出海，深度绑定武田制药闯关美国市场
时代财经 · 10-22
三款国产抗癌药卖出天价BD！信达生物114亿美元出海，深度绑定武田制药闯关美国市场
一个分子，两条赛道！国产唯二BTK抑制剂得其一，20亿美元BD交易撬动自免全球市场
市值风云客户端 · 10-21
一个分子，两条赛道！国产唯二BTK抑制剂得其一，20亿美元BD交易撬动自免全球市场
百济神州在欧洲肿瘤内科学会2025年大会上公布百泽安 治疗肺癌的新数据
百济神州官微 · 10-20
百济神州在欧洲肿瘤内科学会2025年大会上公布百泽安 治疗肺癌的新数据
百济神州（688235）披露变更英文公司名称及英文股份简称，10月20日股价上涨0.32%
证券之星 · 10-20
百济神州（688235）披露变更英文公司名称及英文股份简称，10月20日股价上涨0.32%
百济神州(06160)英文股份简称将变更为“BEONE MEDICINES”
智通财经 · 10-17
百济神州(06160)英文股份简称将变更为“BEONE MEDICINES”
2亿元卖早期资产 加科思“舍小保大”
经济观察网 · 10-17
2亿元卖早期资产 加科思“舍小保大”
八年转型深耕“耐心资本” 粤开证券投出百济神州、小鹏汽车等多个明星项目
新浪证券 · 10-16
八年转型深耕“耐心资本” 粤开证券投出百济神州、小鹏汽车等多个明星项目
智通港股早知道 | 现货白银价格“涨疯” 百济神州(06160)索托克拉获突破性疗法认定
智通财经 · 10-14
智通港股早知道 | 现货白银价格“涨疯” 百济神州(06160)索托克拉获突破性疗法认定
百济神州(06160)授出受限制股份单位及业绩股份单位
智通财经 · 10-08
百济神州(06160)授出受限制股份单位及业绩股份单位
中邮证券：首次覆盖百济神州给予买入评级
证券之星 · 09-30
中邮证券：首次覆盖百济神州给予买入评级
靠创新药结束连续8年亏损局面，百济神州烧百亿研发终迎转机
中金财经 · 09-29
靠创新药结束连续8年亏损局面，百济神州烧百亿研发终迎转机
百济神州“PD-1之父”李康因病去世
经济观察网 · 09-18
百济神州“PD-1之父”李康因病去世
百济神州：合共6.3万股美国存托股份由3932名参与者根据2018员工购股计划购买
新浪港股 · 09-13
百济神州：合共6.3万股美国存托股份由3932名参与者根据2018员工购股计划购买
加载更多
公司概况
公司名称：
百济神州有限公司
所属行业：
医药制造业
上市日期：
2021-12-15
主营业务：
百济神州有限公司的主营业务是研究、开发、生产以及商业化创新型药物。公司的主要产品是百悦泽、百泽安、百汇泽、安加维、倍利妥、凯洛斯、萨温珂、凯泽百、普贝希（安维汀生物类似药）、百拓维（注射用戈舍瑞林微球）、泰菲乐（达拉非尼）、迈吉宁（曲美替尼）、维全特（帕唑帕尼）、飞尼妥（依维莫司）、赞可达（塞瑞替尼）。截至本报告期末，公司及其控股子公司拥有的发明专利包括美国发明专利64个、中国发明专利67个、日本发明专利30个、欧洲发明专利15个及其他国家或地区的发明专利135个。
发行价格：
192.60
{"stockData":{"symbol":"688235","market":"SH","secType":"STK","nameCN":"百济神州","latestPrice":281.35,"timestamp":1762486167000,"preClose":277.5,"halted":0,"volume":2650906,"delay":0,"changeRate":0.0139,"floatShares":114999999,"shares":1541000000,"eps":-1.0717,"marketStatus":"午间休市","change":3.85,"latestTime":"11-07 11:29:27","open":286,"high":286,"low":279.34,"amount":748000000,"amplitude":0.024,"askPrice":281.35,"askSize":5,"bidPrice":281.09,"bidSize":9,"shortable":0,"etf":0,"ttmEps":-1.0717,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1762491600000},"marketStatusCode":3,"adr":0,"adjPreClose":277.5,"symbolType":"stock_kcb","openAndCloseTimeList":[[1762479000000,1762486200000],[1762491600000,1762498800000]],"highLimit":305.25,"lowLimit":249.75,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":1540677809,"isCdr":false,"pbRate":15.92,"roa":"--","roe":"1.76%","epsLYR":-3.64,"committee":0.107143,"marketValue":433470000000,"turnoverRate":0.023,"status":0,"hkstockBrief":{"symbol":"06160","market":"HK","secType":"STK","nameCN":"百济神州","latestPrice":189.3,"timestamp":1762488300006,"preClose":188.6,"halted":0,"volume":4782125,"delay":0,"premium":"-38.34"},"floatMarketCap":32371000000},"requestUrl":"/m/hq/s/688235","defaultTab":"news","newsList":[{"id":"2581982460","title":"百济神州(06160)Q3单季度营收突破百亿规模 上调全年业绩指引","url":"https://stock-news.laohu8.com/highlight/detail?id=2581982460","media":"智通财经网","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2581982460?lang=zh_cn&edition=full","pubTime":"2025-11-06 20:45","pubTimestamp":1762433103,"startTime":"0","endTime":"0","summary":"11月6日晚间，百济神州发布2025年第三季度A股主要财务数据公告。","market":"sh","thumbnail":"https://img.zhitongcaijing.com/image/20251106/20251106204537_12843.png?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250","type":0,"news_type":0,"thumbnails":["https://img.zhitongcaijing.com/image/20251106/20251106204537_12843.png?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250"],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1366253.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["ONC","688235","06160"],"gpt_icon":1},{"id":"2581064310","title":"百济神州：百悦泽®在美国市场地位领先以及其在全球其他重要市场持续扩张调整2025年营业收入预测为362亿元至381亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=2581064310","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2581064310?lang=zh_cn&edition=full","pubTime":"2025-11-06 19:50","pubTimestamp":1762429856,"startTime":"0","endTime":"0","summary":"营业收入预计增长的调整主要得益于百悦泽在美国市场的领先地位以及其在欧洲和全球其他重要市场的持续扩张。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025110600034226.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["06160","688235"],"gpt_icon":0},{"id":"2581066452","title":"百济神州：第三季度总收入达14亿美元，同比增长41%","url":"https://stock-news.laohu8.com/highlight/detail?id=2581066452","media":"金融界","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2581066452?lang=zh_cn&edition=full","pubTime":"2025-11-06 19:10","pubTimestamp":1762427431,"startTime":"0","endTime":"0","summary":"百济神州(06160.HK)在港交所公告，2025年第三季度总收入达14亿美元，同比增长41%。百悦泽®（泽布替尼）该季度全球收入达10亿美元，同比增长51%。按照美国公认会计原则(GAAP)的稀释每股美国存托股份(ADS)收益为1.09美元；非GAAP稀释每股ADS收益为2.65美元。\n\n港股频道更多独家策划、专家专栏，免费查阅>>\n\r\n 责任编辑：山上","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://hk.jrj.com.cn/2025/11/06191054053997.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["LU0307460666.USD","LU2328871848.SGD","06160","688235","BK1583","BK4585","BK0239","LU1251922891.USD","BK1500","BK4526","BK1588","BK1161","LU1303224171.USD","ONC","LU0588546209.SGD","BK4139","LU1969619763.USD","LU1719994722.HKD","LU1770034418.SGD"],"gpt_icon":0},{"id":"2578670663","title":"博时基金万琼旗下博时恒生医疗保健ETF三季报最新持仓，重仓百济神州","url":"https://stock-news.laohu8.com/highlight/detail?id=2578670663","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2578670663?lang=zh_cn&edition=full","pubTime":"2025-10-28 07:33","pubTimestamp":1761608009,"startTime":"0","endTime":"0","summary":"证券之星消息，10月28日博时基金旗下万琼管理的博时恒生医疗保健交易型开放式指数基金(QDII)公布三季报，近1年净值增长率58.12%。与上一季度相比，该基金前十大重仓股新增药明康德；其中百济神州持仓占比10.07%，为该基金第一大重仓股；翰森制药等退出前十大重仓股；详细数据如下：以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025102800008212.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","159506","BK1583","LU0307460666.USD","LU2328871848.SGD","LU1251922891.USD","BK1500","BK1161","06160","BK1588","LU1303224171.USD","LU1719994722.HKD","LU1770034418.SGD","LU1969619763.USD","688235","LU0588546209.SGD"],"gpt_icon":0},{"id":"2578166534","title":"银华基金马君旗下银华国证港股通创新药ETF三季报最新持仓，重仓百济神州","url":"https://stock-news.laohu8.com/highlight/detail?id=2578166534","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2578166534?lang=zh_cn&edition=full","pubTime":"2025-10-27 07:20","pubTimestamp":1761520832,"startTime":"0","endTime":"0","summary":"证券之星消息，10月27日银华基金旗下马君管理的银华国证港股通创新药交易型开放式指数基金公布三季报，近1年净值增长率60.93%。与上一季度相比，该基金前十大重仓股新增科伦博泰生物-B，荣昌生物；并对百济神州增仓259.66万股，为该基金第一大重仓股；药明生物，亚盛医药-B等退出前十大重仓股；详细数据如下：以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025102700001987.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["LU0307460666.USD","LU1303224171.USD","LU0588546209.SGD","LU1251922891.USD","LU2328871848.SGD","BK1500","BK1583","06160","520880","688235","BK1588","LU1719994722.HKD","BK0239","LU1969619763.USD","BK1161","LU1770034418.SGD"],"gpt_icon":0},{"id":"2578458504","title":"每周股票复盘：百济神州（688235）英文名变更为BeOne Medicines","url":"https://stock-news.laohu8.com/highlight/detail?id=2578458504","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2578458504?lang=zh_cn&edition=full","pubTime":"2025-10-26 02:34","pubTimestamp":1761417252,"startTime":"0","endTime":"0","summary":"截至2025年10月24日收盘，百济神州报收于279.8元，较上周的273.67元上涨2.24%。本周关注点公司公告汇总：百济神州英文名称变更为BeOne Medicines Ltd.，英文股份简称将于10月22日起同步变更。公司公告汇总港股公告：变更英文公司名称及英文股份简称百济神州有限公司宣布，公司英文名称已由BeiGene, Ltd.变更为BeOne Medicines Ltd.，自2025年5月27日生效。香港公司注册处已于2025年10月2日发出注册证明书，确认该英文名称变更于香港注册。中文股份简称维持不变，仍为“百济神州”。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025102600000502.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["LU1770034418.SGD","LU1719994722.HKD","LU1251922891.USD","BK1588","LU0588546209.SGD","06160","LU1303224171.USD","BK1500","LU1969619763.USD","BK1161","BK0239","BK1583","688235","LU0307460666.USD","LU2328871848.SGD"],"gpt_icon":0},{"id":"2577415393","title":"百济神州（688235）披露将举行业绩电话会议，10月22日股价下跌0.22%","url":"https://stock-news.laohu8.com/highlight/detail?id=2577415393","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2577415393?lang=zh_cn&edition=full","pubTime":"2025-10-22 22:15","pubTimestamp":1761142522,"startTime":"0","endTime":"0","summary":"截至2025年10月22日收盘，百济神州报收于281.95元，较前一交易日下跌0.22%，最新总市值为4343.94亿元。该股当日开盘280.0元，最高286.58元，最低278.79元，成交额达5.41亿元，换手率为1.67%。近日，百济神州有限公司发布自愿披露公告，宣布公司将于美国东部时间2025年11月6日（星期四）发布截至2025年9月30日止第三季度未经审计财务业绩。公司管理团队将于美国东部时间2025年11月6日上午8时举行业绩电话会议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025102200037532.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1161","BK1588","688235","06160","LU0307460666.USD","LU1770034418.SGD","LU1719994722.HKD","LU0588546209.SGD","LU1251922891.USD","BK1583","BK1500","LU1303224171.USD","LU1969619763.USD","BK0239","LU2328871848.SGD"],"gpt_icon":0},{"id":"2577501213","title":"三款国产抗癌药卖出天价BD！信达生物114亿美元出海，深度绑定武田制药闯关美国市场","url":"https://stock-news.laohu8.com/highlight/detail?id=2577501213","media":"时代财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2577501213?lang=zh_cn&edition=full","pubTime":"2025-10-22 18:17","pubTimestamp":1761128220,"startTime":"0","endTime":"0","summary":"中国创新药的BD（商务拓展）交易天花板被信达生物（01801.HK）打破。10月22日，信达生物宣布，其与武田制药就IBI363、IBI343、IBI3001三款核心抗癌疗法达成全球合作。根据协议，三款药物将 ...","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://stock.10jqka.com.cn/hks/20251022/c671923963.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"tonghuashun","symbols":["BK0239","688506","688235"],"gpt_icon":0},{"id":"2577872698","title":"一个分子，两条赛道！国产唯二BTK抑制剂得其一，20亿美元BD交易撬动自免全球市场","url":"https://stock-news.laohu8.com/highlight/detail?id=2577872698","media":"市值风云客户端","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2577872698?lang=zh_cn&edition=full","pubTime":"2025-10-21 23:22","pubTimestamp":1761060120,"startTime":"0","endTime":"0","summary":"全年实现盈利基本已成定局。在BTK抑制剂出现之前，化疗一直是B细胞恶性肿瘤的标准治疗方案。然而，这种传统疗法不仅伴随显著的毒副作用，且在复发/难治性淋巴瘤中的疗效十分有限。2013年， ...","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://stock.10jqka.com.cn/hks/20251021/c671905387.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tonghuashun","symbols":["688235","BK0239"],"gpt_icon":0},{"id":"2576858454","title":"百济神州在欧洲肿瘤内科学会2025年大会上公布百泽安 治疗肺癌的新数据","url":"https://stock-news.laohu8.com/highlight/detail?id=2576858454","media":"百济神州官微","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2576858454?lang=zh_cn&edition=full","pubTime":"2025-10-20 18:30","pubTimestamp":1760956200,"startTime":"0","endTime":"0","summary":"新数据来自百泽安 两项关键性研究RATIONALE-307和312，巩固了PD-1抑制剂治疗非小细胞肺癌和广泛期小细胞肺癌已证实的临床获益在研药物HPK1抑制剂BGB-26808与百泽安 联合治疗晚期实体瘤的早 ...","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://stock.10jqka.com.cn/hks/20251020/c671858089.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tonghuashun","symbols":["688235","BK0239"],"gpt_icon":0},{"id":"2576323788","title":"百济神州（688235）披露变更英文公司名称及英文股份简称，10月20日股价上涨0.32%","url":"https://stock-news.laohu8.com/highlight/detail?id=2576323788","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2576323788?lang=zh_cn&edition=full","pubTime":"2025-10-20 17:16","pubTimestamp":1760951770,"startTime":"0","endTime":"0","summary":"截至2025年10月20日收盘，百济神州报收于274.55元，较前一交易日上涨0.32%，最新总市值为4229.93亿元。该股当日开盘276.39元，最高279.79元，最低272.17元，成交额达6.21亿元，换手率为1.96%。香港公司注册处处长已于2025年10月2日发出注册非香港公司变更名称注册证明书，确认该英文名称变更于香港注册。因此，于香港联交所进行股份交易的英文股份简称将由“BEIGENE”变更为“BEONE MEDICINES”，自2025年10月22日上午九时正起生效。中文股份简称维持不变，仍为“百济神州”。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025102000021850.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["LU1969619763.USD","LU1303224171.USD","BK0239","LU1251922891.USD","LU0307460666.USD","LU2328871848.SGD","BK1161","BK1588","BK1500","06160","BK1583","688235","LU1719994722.HKD","LU0588546209.SGD","LU1770034418.SGD"],"gpt_icon":0},{"id":"2576055832","title":"百济神州(06160)英文股份简称将变更为“BEONE MEDICINES”","url":"https://stock-news.laohu8.com/highlight/detail?id=2576055832","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2576055832?lang=zh_cn&edition=full","pubTime":"2025-10-17 21:32","pubTimestamp":1760707970,"startTime":"0","endTime":"0","summary":"智通财经APP讯，百济神州(06160)公布，公司英文名称变更完成后，于香港联交所进行股份交易的英文股份简称将由“BEIGENE”变更为“BEONE MEDICINES”，自2025年10月22日星期三上午九时正(香港时间)起生效。于香港联交所进行股份交易的中文股份简称将维持不变，仍为“百济神州”。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1356644.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0239","BK4585","LU1303224171.USD","BK1161","LU2328871848.SGD","LU1719994722.HKD","ONC","06160","LU0307460666.USD","LU1251922891.USD","LU1969619763.USD","BK4526","BK1500","BK4139","LU0588546209.SGD","LU1770034418.SGD","688235","BK1583","BK1588"],"gpt_icon":0},{"id":"2576770201","title":"2亿元卖早期资产 加科思“舍小保大”","url":"https://stock-news.laohu8.com/highlight/detail?id=2576770201","media":"经济观察网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2576770201?lang=zh_cn&edition=full","pubTime":"2025-10-17 08:37","pubTimestamp":1760661420,"startTime":"0","endTime":"0","summary":" 10月15日晚，加科思-B（01167.HK）发布公告，披露了一次增资与股权转让交易。加科思的主要业务是肿瘤创新药，而本次交易涉及的是此前未曾披露的心血管治疗项目，该项目原由加科瑞康持有。 ...","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tonghuashun","url":"http://stock.10jqka.com.cn/hks/20251017/c671803881.shtml","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://stock.10jqka.com.cn/hks/20251017/c671803881.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tonghuashun","symbols":["688235","688578","BK0239","BK0060","300558"],"gpt_icon":0},{"id":"2575371958","title":"八年转型深耕“耐心资本” 粤开证券投出百济神州、小鹏汽车等多个明星项目","url":"https://stock-news.laohu8.com/highlight/detail?id=2575371958","media":"新浪证券","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2575371958?lang=zh_cn&edition=full","pubTime":"2025-10-16 16:50","pubTimestamp":1760604600,"startTime":"0","endTime":"0","summary":" 10月16日至18日，2025可持续全球领导者大会在上海世博园区召开。粤开证券董事长郭川舟受邀出席大会，并做主旨演讲。自2017年起，集团及粤开证券在战略与主营业务上实现了全面转型。他举例称，自并购粤开证券后，投资板块持续聚焦“高精尖”领域，代表性项目包括投资了科创板生物医药市值领军企业百济神州，以及小鹏汽车、文远知行等知名公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/roll/2025-10-16/doc-infuaqmp7214152.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK1500","161027","688235","BK1161","XPEV","BK1588","BK1119","BK1583","LU2328871848.SGD","LU1770034418.SGD","LU1251922891.USD","BK1610","LU1719994722.HKD","09868","BK4505","BK1575","BK4551","EVS.SI","BK4555","LU1969619763.USD","06160","LU0588546209.SGD","ONC","BK4585","LU1303224171.USD","LU0593848301.USD","BK4526","BK0239","BK1587","BK4139","BK4099","LU0307460666.USD","BK1539"],"gpt_icon":0},{"id":"2575390582","title":"智通港股早知道 | 现货白银价格“涨疯” 百济神州(06160)索托克拉获突破性疗法认定","url":"https://stock-news.laohu8.com/highlight/detail?id=2575390582","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2575390582?lang=zh_cn&edition=full","pubTime":"2025-10-14 07:20","pubTimestamp":1760397632,"startTime":"0","endTime":"0","summary":"罕见逼空行情上演，现货白银价格“涨疯”北京时间10月14日凌晨，智通财经APP获悉，白银市场掀起近半个世纪以来罕见的逼空行情。伦敦市场流动性紧缩，直接催化了白银价格的历史性突破。白银板块涉及港股中国白银集团。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1354556.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU0572939691.SGD","LU0314109678.HKD","LU1807302812.USD","LU1226287792.SGD","BK1584","IE0008368742.USD","LU0880133367.SGD","06160","LU0315179316.USD","BK1521","BK1500","IE00BZ08YR35.GBP","IE0008369823.USD","LU1960683339.HKD","IE00B031HY20.USD","BK1163","01093","BK1161","LU0264606111.USD","LU1813983027.USD","IE00BZ08YS42.EUR","02577","LU1008478684.HKD","LU1951186391.HKD","LU1993786604.SGD","LU0072913022.USD","01336","LU0572940350.SGD","LU0326950275.SGD","LU0307460666.USD","BK1184","BK4526","LU1251922891.USD","BK0239","ONC","LU0501845795.SGD","LU1303224171.USD","00815","IE00BZ08YT58.USD","00666","LU1719994722.HKD","BK1116","BK1515","BK1592","BK4139","BK4585","IE00B543WZ88.USD","688235","LU2039709279.SGD","BK1583"],"gpt_icon":0},{"id":"2573300923","title":"百济神州(06160)授出受限制股份单位及业绩股份单位","url":"https://stock-news.laohu8.com/highlight/detail?id=2573300923","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2573300923?lang=zh_cn&edition=full","pubTime":"2025-10-08 20:17","pubTimestamp":1759925822,"startTime":"0","endTime":"0","summary":"智通财经APP讯，百济神州(06160)发布公告，于2025年9月30日，董事会薪酬委员会根据2016期权及激励计划的条款向237名承授人授出涉及合共3.6万股美国存托股份的受限制股份单位，并向一名承授人授出涉及合共2935股美国存托股份的业绩股份单位。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1352783.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","LU1719994722.HKD","LU0307460666.USD","BK1588","06160","LU0588546209.SGD","LU1251922891.USD","688235","BK1583","ONC","BK4139","LU1969619763.USD","BK1500","BK0239","LU1303224171.USD","BK4585","LU1770034418.SGD","LU2328871848.SGD","BK4526"],"gpt_icon":0},{"id":"2571139235","title":"中邮证券：首次覆盖百济神州给予买入评级","url":"https://stock-news.laohu8.com/highlight/detail?id=2571139235","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2571139235?lang=zh_cn&edition=full","pubTime":"2025-09-30 12:19","pubTimestamp":1759205980,"startTime":"0","endTime":"0","summary":"中邮证券有限责任公司盛丽华,陈灿近期对百济神州进行研究并发布了研究报告《泽布替尼环比稳定增长，Q2维持GAAP转正势头》，首次覆盖百济神州给予买入评级。B7H4ADC预计26年启动III期。公司为创新药出海龙头企业，全球商业化能力突出、在研管线即将进入收获期首次覆盖，给予“买入”评级。最新盈利预测明细如下：该股最近90天内共有10家机构给出评级，买入评级8家，增持评级2家；过去90天内机构目标均价为303.87。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025093000017687.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["161027","06160","688235"],"gpt_icon":0},{"id":"2571877777","title":"靠创新药结束连续8年亏损局面，百济神州烧百亿研发终迎转机","url":"https://stock-news.laohu8.com/highlight/detail?id=2571877777","media":"中金财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2571877777?lang=zh_cn&edition=full","pubTime":"2025-09-29 11:20","pubTimestamp":1759116002,"startTime":"0","endTime":"0","summary":"连续多年亏损之后，百济神州终于实现盈利。根据其发布的A股半年报，今年上半年公司实现净利润4.50亿元，同比增长115.63%，结束了连续8年的亏损。作为一家创新药公司，百济神州专注于研发具有“同类首创”或“同类最佳”潜力的创新药物，研发周期较长、投入较大。上半年，百济神州依靠创新药扭亏，且主要受益于海外市场的高支付能力。据了解，百济神州旗下获得多国批准的创新药包括百悦泽、百泽安两款。","market":"fut","thumbnail":" http://caiji.3g.cnfol.com/colect/202509/29/20250929393548.jpg","type":0,"news_type":0,"thumbnails":[" http://caiji.3g.cnfol.com/colect/202509/29/20250929393548.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/ggzixun/20250929/31680369.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["159992","BK1588","688235","LU1303224171.USD","LU0588546209.SGD","BK1500","BK4585","BK4139","BK1161","LU2328871848.SGD","BK1574","BK4526","06978","LU1251922891.USD","06160","LU1770034418.SGD","LU1719994722.HKD","ONC","LU1969619763.USD","BK0239","LU0307460666.USD","BK1583"],"gpt_icon":0},{"id":"2568421117","title":"百济神州“PD-1之父”李康因病去世","url":"https://stock-news.laohu8.com/highlight/detail?id=2568421117","media":"经济观察网","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2568421117?lang=zh_cn&edition=full","pubTime":"2025-09-18 15:22","pubTimestamp":1758180120,"startTime":"0","endTime":"0","summary":"经济观察报获悉，近日，百济神州（ONC.NASDAQ/06160.HK/688235.SH）前高级副总裁、生物药研发负责人李康因脑溢血去世，享年69岁。李康是百济神州PD-1药物替雷利珠单抗（百泽安）的主要发明 ...","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tonghuashun","url":"http://stock.10jqka.com.cn/hks/20250918/c671236687.shtml","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://stock.10jqka.com.cn/hks/20250918/c671236687.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"tonghuashun","symbols":["BK0239","688235"],"gpt_icon":0},{"id":"2567186946","title":"百济神州：合共6.3万股美国存托股份由3932名参与者根据2018员工购股计划购买","url":"https://stock-news.laohu8.com/highlight/detail?id=2567186946","media":"新浪港股","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2567186946?lang=zh_cn&edition=full","pubTime":"2025-09-13 11:56","pubTimestamp":1757735760,"startTime":"0","endTime":"0","summary":"热点栏目\n\n自选股\n数据中心\n行情中心\n资金流向\n模拟交易\n\n客户端\n\n\n 百济神州（06160）发布公告，截至2025年3月3日至2025年8月29日的认购期的最后一日，合共6.3万股美国存托股份由3932名参与者根据2018员工购股计划购买（所购美国存托股份）。所购美国存托股份涉及的股份数目为81.85万，代表于本公告之日公司已发行股份总数的约0.05%。\n\n\n海量资讯、精准解读，尽在新浪财经APP\n\n责任编辑：卢昱君","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hkstock/ggscyd/2025-09-13/doc-infqimaq8574010.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK4526","LU0307460666.USD","LU1303224171.USD","LU1719994722.HKD","LU2328871848.SGD","688235","BK4139","06160","BK1161","BK1500","BK0239","BK1588","LU1770034418.SGD","BK1583","LU1251922891.USD","LU1969619763.USD","LU0588546209.SGD","ONC","BK4585"],"gpt_icon":0}],"profile":{"ret":0,"serverTime":1762488983806,"stockEarnings":[{"period":"1week","weight":-0.0153},{"period":"1month","weight":-0.0958},{"period":"3month","weight":0.2354},{"period":"6month","weight":0.1395},{"period":"1year","weight":0.5427},{"period":"ytd","weight":0.7234}],"compareEarnings":[{"period":"1week","weight":0.0052},{"period":"1month","weight":0.0322},{"period":"3month","weight":0.1025},{"period":"6month","weight":0.1992},{"period":"1year","weight":0.1844},{"period":"ytd","weight":0.1957}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"百济神州有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"23120人(较上一季度减少3.95%)","perCapita":"4976股","listingDate":"2021-12-15","address":"c/o BeOne Medicines I GmbH, Aeschengraben 27, 4051 Basel, Switzerland","registeredCapital":"15万元","survey":" 百济神州有限公司的主营业务是研究、开发、生产以及商业化创新型药物。公司的主要产品是百悦泽、百泽安、百汇泽、安加维、倍利妥、凯洛斯、萨温珂、凯泽百、普贝希（安维汀生物类似药）、百拓维（注射用戈舍瑞林微球）、泰菲乐（达拉非尼）、迈吉宁（曲美替尼）、维全特（帕唑帕尼）、飞尼妥（依维莫司）、赞可达（塞瑞替尼）。截至本报告期末，公司及其控股子公司拥有的发明专利包括美国发明专利64个、中国发明专利67个、日本发明专利30个、欧洲发明专利15个及其他国家或地区的发明专利135个。","listedPrice":192.6},"APP":{"userAgent":"CCBot/2.0 (https://commoncrawl.org/faq/)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.35.5","shortVersion":"4.35.5","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"百济神州(688235)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供百济神州(688235)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"百济神州,688235,百济神州股票,百济神州股票老虎,百济神州股票老虎国际,百济神州行情,百济神州股票行情,百济神州股价,百济神州股市,百济神州股票价格,百济神州股票交易,百济神州股票购买,百济神州股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"百济神州(688235)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供百济神州(688235)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}